Ajithkumar A. Puthillath, MD
Specialist
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 735
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
CA license A107213
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sutter Amador Hospital Jackson, CA
- St Joseph's Medical Center of Stockton Stockton, CA
- Adventist Health Lodi Memorial Lodi, CA
- Doctors Hospital of Manteca Manteca, CA
- Mark Twain Medical Center San Andreas, CA
Medical groups
- San Joaquin Faculty Medical Group (128 clinicians)
- Stockton Hematology Oncology Medical Group Inc (10 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 735
- Services billed
- 240,870
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 23,040 | 63 |
| Injection, pembrolizumab, 1 mg | 19,200 | 15 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 15,300 | 11 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 4,010 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 3,452 | 63 |
| Injection, palonosetron hcl, 25 mcg | 2,000 | 31 |
| Injection, leucovorin calcium, per 50 mg | 1,171 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 891 | 413 |
| Injection, fluorouracil, 500 mg | 741 | 11 |
| Administration of chemotherapy into vein, 1 hour or less | 703 | 86 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Stockton, CA | 369 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Stockton, CA | 110 |
| Tamoxifen Citrate Other prescribers in Stockton, CA | 91 |
| Ondansetron Odt (ondansetron) Other prescribers in Stockton, CA | 75 |
| Exemestane | 57 |
| Gabapentin Other prescribers in Stockton, CA | 56 |
| Anastrozole Other prescribers in Stockton, CA | 53 |
| Hydroxyurea Other prescribers in Stockton, CA | 53 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Stockton, CA | 49 |
| Revlimid (lenalidomide) | 47 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 35 companies reported 98 payments worth $3,306 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $1,290 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $182 |
| Regeneron Healthcare Solutions, Inc. | $162 |
| Gilead Sciences, Inc. | $150 |
| Servier Pharmaceuticals LLC | $121 |
| Janssen Biotech, Inc. | $115 |
| Incyte Corporation | $106 |
| Beone Medicines USA, Inc. | $102 |
| Food and Beverage | $2,133 |
|---|---|
| Long term medical supply or device loan | $1,098 |
| Education | $74.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Gilead Sciences, Inc. Feb 27, 2025 | Education Trodelvy · ONC · in-kind Company’s description;3942196;GTF;10676372 | $74.99 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $14.00 in research payments for these studies, mostly to the institutions running them.
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.